EGFR and cancer: The second class of small molecules directed to tyrosine kinase proteins was represented by Gefitinib (Iressa®) and Erlotinib (Tarceva®) both directed to the EGFR ATP-binding site and able to inhibit the abnormal activation of MAPK and PI3K/AKT pathways overexpressed in cancer cells (Nicholson et al., 2001; Yarden, 2001).